Drug intelligence / Profile preview

AKS-427c

Development stage: Preclinical
Lead developer: Akston Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

AKS-427c is a monoclonal antibody being developed by Akston Biosciences for the treatment of various cancers in cats (feline oncology). The antibody is designed to bind to the insulin-like growth factor (IGF) receptor, a protein that plays a significant role in cell growth and proliferation. In many feline tumors, the IGF signaling pathway is overactive, promoting tumor cell survival and expansion. By specifically binding to and inhibiting the IGF receptor, AKS-427c blocks this growth-promoting signaling, potentially slowing tumor progression or sensitizing tumors to other treatments. It is part of Akston's specialized pipeline for veterinary biologics.

Targets

IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on AKS-427c.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKS-427c.

Explore the full profile